Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies

Focus on panitumumab

George P. Kim, Axel F Grothey

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, panitumumab, represents a significant advance in the treatment of colorectal cancer. The strategy to target this receptor is based on sound cancer biology demonstrating its essential role in colorectal carcinogenesis. Panitumumab, unlike its predecessor, cetuximab, is fully human and thus reduces the incidence of hypersensitivity reactions. But, in several clinical trials, unexpected toxicities have become more apparent, raising concerns of how readily panitumumab can ucceed cetuximab. This paper reviews the development of this agent and the pivotal clinical trials that help our understanding of its optimal use in colorectal cancer treatment. 7COPY; 2008 Dove Medical Press Limited. All rights reserved.

Original languageEnglish (US)
Pages (from-to)223-228
Number of pages6
JournalBiologics: Targets and Therapy
Volume2
Issue number2
StatePublished - 2008

Fingerprint

Epidermal Growth Factor Receptor
Colorectal Neoplasms
Antibodies
Clinical Trials
Hypersensitivity
Carcinogenesis
Monoclonal Antibodies
Incidence
panitumumab
Neoplasms
Cetuximab

Keywords

  • Bevacizumab
  • Cetuximab
  • Chemotherapy
  • Colorectal cancer
  • Irinotecan
  • Oxaliplatin
  • Panitumumab

ASJC Scopus subject areas

  • Oncology
  • Immunology and Allergy
  • Pharmacology (medical)
  • Gastroenterology
  • Rheumatology

Cite this

Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies : Focus on panitumumab. / Kim, George P.; Grothey, Axel F.

In: Biologics: Targets and Therapy, Vol. 2, No. 2, 2008, p. 223-228.

Research output: Contribution to journalArticle

@article{98d44086cd6445ca8455817796e78991,
title = "Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: Focus on panitumumab",
abstract = "The human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, panitumumab, represents a significant advance in the treatment of colorectal cancer. The strategy to target this receptor is based on sound cancer biology demonstrating its essential role in colorectal carcinogenesis. Panitumumab, unlike its predecessor, cetuximab, is fully human and thus reduces the incidence of hypersensitivity reactions. But, in several clinical trials, unexpected toxicities have become more apparent, raising concerns of how readily panitumumab can ucceed cetuximab. This paper reviews the development of this agent and the pivotal clinical trials that help our understanding of its optimal use in colorectal cancer treatment. 7COPY; 2008 Dove Medical Press Limited. All rights reserved.",
keywords = "Bevacizumab, Cetuximab, Chemotherapy, Colorectal cancer, Irinotecan, Oxaliplatin, Panitumumab",
author = "Kim, {George P.} and Grothey, {Axel F}",
year = "2008",
language = "English (US)",
volume = "2",
pages = "223--228",
journal = "Biologics: Targets and Therapy",
issn = "1177-5475",
publisher = "Dove Medical Press Ltd.",
number = "2",

}

TY - JOUR

T1 - Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies

T2 - Focus on panitumumab

AU - Kim, George P.

AU - Grothey, Axel F

PY - 2008

Y1 - 2008

N2 - The human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, panitumumab, represents a significant advance in the treatment of colorectal cancer. The strategy to target this receptor is based on sound cancer biology demonstrating its essential role in colorectal carcinogenesis. Panitumumab, unlike its predecessor, cetuximab, is fully human and thus reduces the incidence of hypersensitivity reactions. But, in several clinical trials, unexpected toxicities have become more apparent, raising concerns of how readily panitumumab can ucceed cetuximab. This paper reviews the development of this agent and the pivotal clinical trials that help our understanding of its optimal use in colorectal cancer treatment. 7COPY; 2008 Dove Medical Press Limited. All rights reserved.

AB - The human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, panitumumab, represents a significant advance in the treatment of colorectal cancer. The strategy to target this receptor is based on sound cancer biology demonstrating its essential role in colorectal carcinogenesis. Panitumumab, unlike its predecessor, cetuximab, is fully human and thus reduces the incidence of hypersensitivity reactions. But, in several clinical trials, unexpected toxicities have become more apparent, raising concerns of how readily panitumumab can ucceed cetuximab. This paper reviews the development of this agent and the pivotal clinical trials that help our understanding of its optimal use in colorectal cancer treatment. 7COPY; 2008 Dove Medical Press Limited. All rights reserved.

KW - Bevacizumab

KW - Cetuximab

KW - Chemotherapy

KW - Colorectal cancer

KW - Irinotecan

KW - Oxaliplatin

KW - Panitumumab

UR - http://www.scopus.com/inward/record.url?scp=77956371812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956371812&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 223

EP - 228

JO - Biologics: Targets and Therapy

JF - Biologics: Targets and Therapy

SN - 1177-5475

IS - 2

ER -